Review: Some Nonpharmacologic Tx Effective in Peds GI Disorders

This article originally appeared here.
Share this content:
Review: Some Nonpharmacologic Tx Effective in Peds GI Disorders
Review: Some Nonpharmacologic Tx Effective in Peds GI Disorders

MONDAY, Feb. 9, 2015 (HealthDay News) -- Certain nonpharmacologic treatments are effective in pediatric abdominal pain-related functional gastrointestinal disorders (AP-FGIDs), according to a review published online Feb. 9 in Pediatrics.

Juliette M.T.M. Rutten, M.D., from Emma's Children's Hospital in Amsterdam, and colleagues conducted a systematic review of the literature relating to nonpharmacologic interventions for pediatric AP-FGIDs. Data were included from 24 randomized controlled trials that included 1,390 children.

The researchers observed significant improvement of abdominal pain after hypnotherapy versus standard care/wait list approaches and after cognitive behavioral therapy versus control/wait list approaches. At the six-month follow-up only, written self-disclosure improved pain frequency. Significantly more treatment responders were seen with Lactobacillus rhamnosus GG (LGG) and VSL#3 versus placebo (LGG relative risk, 1.31; VSL#3 P < 0.05). Irritable bowel syndrome symptom frequency was significantly improved with guar gum but there was no effect seen for other fiber supplements or a lactose-free diet. Compared with a wait-list approach, yoga was not associated with a significant decrease in functional disability. There were no reports of serious adverse events. Evidence quality was found to be very low to moderate.

"Although high-quality studies are lacking, some evidence shows efficacy of hypnotherapy, cognitive behavioral therapy, and probiotics (LGG and VSL#3) in pediatric AP-FGIDs," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »